期刊
LEUKEMIA & LYMPHOMA
卷 63, 期 3, 页码 729-737出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2021.1998484
关键词
Ribonucleotide reductase (RNR); myelodysplastic syndrome; methylation; 5-azacytidine; response to treatment
资金
- Genesis Pharma [GE00036/2018]
The study found that in MDS treatment, RNR expression is correlated with clinical outcomes, with low RRM1 levels associated with RRM1 methylation status affecting patient response to 5-azacytidine treatment. Splicing factor mutations may be related to a decrease in RRM1 mRNA levels.
Ribonucleotide Reductase (RNR) is a two-subunit (RRM1, RRM2) enzyme, responsible for the conversion of ribonucleotides to deoxyribonucleotides required for DNA replication. To evaluate RNR as a biomarker of response to 5-azacytidine, we measured RNR mRNA levels by a quantitative real-time PCR in bone marrow samples of 98 patients with myelodysplastic syndrome (MDS) treated with 5-azacytidine with parallel quantification of the gene promoter's methylation. Patients with low RRM1 levels had a high RRM1 methylation status (p = 0.005) and a better response to treatment with 5-azacytidine (p = 0.019). A next-generation sequencing for genes of interest in MDS was also carried out in a subset of 61 samples. Splicing factor mutations were correlated with lower RRM1 mRNA levels (p = 0.044). Our results suggest that the expression of RNR is correlated with clinical outcomes, thus its expression could be used as a prognostic factor for response to 5-azacytidine and a possible therapeutic target in MDS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据